Literature DB >> 25734407

Evaluation of Clinical and Pathologic Risk Factors May Reduce the Rate of Multimodality Treatment of Early Cervical Cancer.

Ofer Gemer1, Ofer Lavie, Michael Gdalevich, Ram Eitan, Ela Mamanov, Benjamin Piura, Alex Rabinovich, Hanoch Levavi, Bozhena Saar-Ryss, Reuvit Halperin, Shachar Finci, Uzi Beller, Ilan Bruchim, Tally Levy, Amichay Meirovitz, Inbar Ben Shachar, Alon Ben Arie.   

Abstract

OBJECTIVE: To assess the rate of postoperative adjuvant treatment in patients who underwent radical hysterectomy for early cervical cancer and to suggest criteria for the triage of patients who have a high probability of multimodality treatment.
METHODS: This was a multicenter retrospective study of 514 patients with FIGO stages IA2-IIA cervical cancer who underwent radical hysterectomy between 1999 and 2010. The patients were divided into 2 groups according to whether or not postoperative radiation was administered. The 2 groups were compared with regard to clinical and histopathologic variables divided into major and minor criteria (intermediate risk factors) based on lymph nodes status, parametrial involvement, tumor size, deep stromal invasion, and lymph-vascular space invasion.
RESULTS: We identified 294 (57.2%) patients who received adjuvant postoperative radiotherapy (RT) or chemoradiation. Fifty-three percent of these patients who were treated by adjuvant radiation had only intermediate risk factors. Combining the various combinations of 2 out of 3 of the following criteria, we found that 89% of patients with tumors ≥2 cm and lymph-vascular space invasion received RT, 76% of patients with tumors ≥2 cm and depth of invasion >10 mm received RT, and 87% of patients with tumors depth of invasion >10 mm and lymph-vascular space invasion received RT.
CONCLUSIONS: This study suggests that in patients with early cervical cancer, clinicopathologic evaluation of tumor size and lymph-vascular space invasion should be undertaken before performing radical hysterectomy. This approach can serve to tailor treatment, reducing the rate of employing both radical hysterectomy and chemoradiation.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 25734407     DOI: 10.1097/COC.0000000000000011

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  3 in total

1.  Prognostic value of lymphovascular space invasion in patients with early stage cervical cancer in Jilin, China: A retrospective study.

Authors:  Wenxing Yan; Shuang Qiu; Yaming Ding; Qi Zhang; Lihui Si; Sha Lv; Linlin Liu
Journal:  Medicine (Baltimore)       Date:  2019-10       Impact factor: 1.889

2.  Region-specific Risk Factors for Pelvic Lymph Node Metastasis in Patients with Stage IB1 Cervical Cancer.

Authors:  Jing Zhao; Jing Cai; Hongbo Wang; Weihong Dong; Yuan Zhang; Shaohai Wang; Xiaoqi He; Si Sun; Yuhui Huang; Bangxing Huang; Kay C Willborn; Ping Jiang; Zehua Wang
Journal:  J Cancer       Date:  2021-03-05       Impact factor: 4.207

3.  Cancer of the cervix uteri: 2021 update.

Authors:  Neerja Bhatla; Daisuke Aoki; Daya Nand Sharma; Rengaswamy Sankaranarayanan
Journal:  Int J Gynaecol Obstet       Date:  2021-10       Impact factor: 4.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.